PDCD1 and lung adenocarcinoma: A set of transcriptional signatures with the ability to stratify tumors, including lung adenocarcinoma, according to response to anti-PD-1 treatment (referred to as innate anti-PD-1 resistance, IPRES) has been reported [116].